Sympathetic Ophthalmia as a Complication of Untreated Choroidal Melanoma
Abstract
1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- He, B.; Tanya, S.M.; Wang, C.; Kezouh, A.; Torun, N.; Ing, E. The Incidence of Sympathetic Ophthalmia After Trauma: A Meta-analysis. Am. J. Ophthalmol. 2022, 234, 117–125. [Google Scholar] [CrossRef]
- Yan, J.; Hobbs, S.D. Sympathetic Ophthalmia. In StatPearls; StatPearls Publishing: Orlando, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK589651/ (accessed on 23 July 2024).
- Paulbuddhe, V.; Addya, S.; Gurnani, B.; Singh, D.; Tripathy, K.; Chawla, R. Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies? Clin. Ophthalmol. 2021, 15, 4201–4218. [Google Scholar] [CrossRef] [PubMed]
- Kaliki, S.; Shields, C.L. Uveal melanoma: Relatively rare but deadly cancer. Eye 2017, 31, 241–257. [Google Scholar] [CrossRef]
- Stålhammar, G.; Gill, V.T. Digital morphometry and cluster analysis identifies four types of melanocyte during uveal melanoma progression. Commun. Med. 2023, 3, 60. [Google Scholar] [CrossRef]
- Viswanathan, D.; Haider, A.S.; Dunlop, A.; McKeag, D. Sympathetic ophthalmia associated with untreated choroidal melanoma. Can. J. Ophthalmol. 2018, 53, e173–e176. [Google Scholar] [CrossRef]
- Brour, J.; Desjardins, L.; Lehoang, P.; Bodaghi, B.; Lumbroso-Lerouic, L.; Dendale, R.; Cassoux, N. Sympathetic Ophthalmia after Proton Beam Irradiation for Choroïdal Melanoma. Ocul. Immunol. Inflamm. 2012, 20, 273–276. [Google Scholar] [CrossRef]
- Ahmad, N.; Soong, T.K.; Salvi, S.; Rudle, P.A.; Rennie, I.G. Sympathetic ophthalmia after ruthenium plaque brachytherapy. Br. J. Ophthalmol. 2007, 91, 399–400. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.-C.; Chao, Y.-J.; Tsai, C.-C.; Chen, S.-J.; Hwang, D.-K. Sympathetic ophthalmia following radiation-induced scleral necrosis in choroidal melanoma. Taiwan J. Ophthalmol. 2023, 13, 548–551. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Arumi, J.; Montolio Gil, M.; Morral Palau, M.; Segura Garcia, A. Sympathetic ophthalmia after surgical resection of iridociliary melanoma. A Case report. Graefe’s Arch. Clin. Exp. Ophthalmol. 2006, 244, 1353–1356. [Google Scholar] [CrossRef]
- Fries, P.D.; Char, D.H.; Crawford, J.B.; Waterhouse, W. Sympathetic Ophthalmia Complicating Helium Ion Irradiation of a Choroidal Melanoma. Arch. Ophthalmol. 1987, 105, 1561–1564. [Google Scholar] [CrossRef]
- Alkatan, H.M.; Al Qahtani, A.A.; Maktabi, A.M. Enucleated globes with choroidal melanoma: A retrospective histopathological study and correlation with cytogenetic profile in 2 eye centers. Ann. Med. Surg. 2020, 55, 227–233. [Google Scholar] [CrossRef]
- Tarlan, B.; Kıratlı, H. Uveal Melanoma; Current Trends in The Diagnosis and Management. Türk. Oftalmol. Derg. 2016, 46, 123–137. [Google Scholar] [CrossRef]
- Parchand, S.; Agrawal, D.; Ayyadurai, N.; Agarwal, A.; Gangwe, A.; Behera, S.; Bhatia, P.; Mulkutkar, S.; Barwar, G.; Singh, R.; et al. Sympathetic ophthalmia: A comprehensive update. Indian J. Ophthalmol. 2022, 70, 1931. [Google Scholar] [CrossRef] [PubMed]
- Macarie, S.S.; Huțu, D. Sympathetic Ophthalmia-case report. Rom. J. Ophthalmol. 2022, 66, 84–88. [Google Scholar] [PubMed]
- Suzuki, H.; Yoshioka, K.; Miyano, M.; Maeda, I.; Yamagami, K.; Morikawa, T.; Okada, N.; Konishi, Y.; Imanishi, M. Tubulointerstitial nephritis and uveitis (TINU) syndrome caused by the Chinese herb “Goreisan”. Clin. Exp. Nephrol. 2009, 13, 73–76. [Google Scholar] [CrossRef] [PubMed]
Time | Right Eye | Left Eye |
---|---|---|
29 September 2021 | Physiological | Uveal melanoma diagnosis in the left eye and patient’s refusal of treatment |
31 March 2023 | After 2 years of “alternative therapy” without ophthalmic care, patient has returned with SO in the right eye (VOD = 0.1). Implementation of steroid treatment. | Completely filled with tumor masses. Refusal of treatment. |
6 June 2023 | Continuation of treatment with steroids (VOD = 0.3), reduction in SO symptoms, incipient post-steroid cataract | Completely filled with tumor masses. Refusal of treatment. |
5 June 2024 | Symptoms of SO greatly reduced; post-steroid cataract and numerous vitreous floaters (VOD = 0.1) | Completely filled with tumor masses—patient agrees for enucleation of the left eye. Surgery performed on 12 June 2024. |
10 July 2024 | Post-steroid cataract (VOD = 0.1). Surgical intervention for the cataract was recommended. | Left eye enucleated. Histopathological examination revealed spindle cell melanoma. |
Paper | Melanoma Status | Precipitating Factor for SO | Patient Age | Outcome |
---|---|---|---|---|
Fries PD et al., 1987 [11] | Choroidal melanoma OS | Helium ion irradiation | 76 | Enucleation of the left eye; BCVA 20/30 OD at SO appearance. |
Garcia-Arumi J et al., 2006 [10] | Spindle cell melanoma of the iris and ciliary body OS | Melanoma resection | 49 | OD: BCVA 20/200 after systemic steroid and immunosuppressive (cyclosporine and azathioprine) treatment of SO, before the surgery for cataract that developed during treatment; OS: BCVA 20/25. |
Ahmad N, Soong TK, Salvi S, Rudle PA, Rennie IG., 2007 [8] | Ciliary body malignant melanoma | 106Ru plaque brachytherapy | 41 | Vision OU 6/5 after intensive steroid treatment. |
Brour J et al., 2012 [7] | Large choroidal juxta-papillary melanoma OS | Proton beam irradiation, then transpupillary thermotherapy | 56 | SO in right eye 7 years after melanoma irradiation treated with steroids, azathioprin, local steroids, focal laser treatment, and multiple intravitreous anti-VEGF injections. BCVA OD after treatment and cataract surgery was 20/40. |
Brour J et al., 2012 [7] | Choroidal melanoma with retinal detachment (OD) | Proton beam irradiation and TTT of the scar, then, after complications (painful neovascular glaucoma), enucleation of the blind right eye | 63 | One year later SO developed in the left eye, VOS = 20/40. After treatment with intravenous and local steroids with antiglaucomatous eyedrops, VOS has returned to 20/20. |
Brour J et al., 2012 [7] | Pigmented supramacular mass of 7.1 mm thickness in OD | Successful treatment with proton beam radiotherapy, complicated with irradiation retinopathy and neovascular glaucoma requiring multiple therapeutic procedures, including panretinal photocoagulation, intravitreal anti-VEGF injection, and cyclocryotherapy | 75 | After 4 years, SO occurred in the left eye; after treatment with intensive systemic steroids, local steroids, and first-line cyclophosphamide monthly, vision progressed from 20/100 to 20/40 with regression of ocular inflammation and macular edema. |
Chen YC et al., 2022 [9] | Primary choroidal melanoma OD | Gamma Knife radiotherapy | 55 | Five years after radiotherapy SO appeared in the left eye (VOS = 0.7) along with pinkish elevated conjunctival mass in OD. After steroid pulse therapy combined with methotrexate, there was a decrease in the size of the mass in the right eye as well as SO symptoms in the left eye, along with VOS recovery to 6/6. |
Viswanathan D et al., 2018 [6] | Six years after SO, choroidal melanoma of the left eye was diagnosed | Ocular trauma 18 months before SO or untreated choroidal melanoma | 41 | Right eye SO was treated with oral steroids and mycophenolate, cyclosporin, and methotrexate. Despite maximal tolerated treatment, OD developed persistent cystoid macular edema—treated with triamcinolone. After phacoemulsification of steroid-induced cataract, VOD was 20/40, and after 4 years, reduced to hand movement recognition. Six years after initial SO, left eye choroidal melanoma was diagnosed and eye was exenterated. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chorągiewicz, T.; Oszczędłowski, P.; Dolar-Szczasny, J.; Toro, M.D.; Denysiuk, O.; Słoka, A.; Chorągiewicz, A.; Yousef, Y.A.; Rejdak, R. Sympathetic Ophthalmia as a Complication of Untreated Choroidal Melanoma. J. Clin. Med. 2025, 14, 5579. https://doi.org/10.3390/jcm14155579
Chorągiewicz T, Oszczędłowski P, Dolar-Szczasny J, Toro MD, Denysiuk O, Słoka A, Chorągiewicz A, Yousef YA, Rejdak R. Sympathetic Ophthalmia as a Complication of Untreated Choroidal Melanoma. Journal of Clinical Medicine. 2025; 14(15):5579. https://doi.org/10.3390/jcm14155579
Chicago/Turabian StyleChorągiewicz, Tomasz, Paweł Oszczędłowski, Joanna Dolar-Szczasny, Mario Damiano Toro, Olga Denysiuk, Adam Słoka, Alicja Chorągiewicz, Yacoub A. Yousef, and Robert Rejdak. 2025. "Sympathetic Ophthalmia as a Complication of Untreated Choroidal Melanoma" Journal of Clinical Medicine 14, no. 15: 5579. https://doi.org/10.3390/jcm14155579
APA StyleChorągiewicz, T., Oszczędłowski, P., Dolar-Szczasny, J., Toro, M. D., Denysiuk, O., Słoka, A., Chorągiewicz, A., Yousef, Y. A., & Rejdak, R. (2025). Sympathetic Ophthalmia as a Complication of Untreated Choroidal Melanoma. Journal of Clinical Medicine, 14(15), 5579. https://doi.org/10.3390/jcm14155579